Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
Apply on Grants.gov →Application closes November 10, 2026
- Posted
- May 4, 2026
- Closes
- November 10, 2026
- Program funding
- $40,000,000
- Expected awards
- 4
- Cost sharing
- No
- Instrument
- Cooperative Agreement
- Assistance listing
- 93.853
- Category
- Health
- Archives
- January 10, 2027
Program funding history
Awards made under Assistance Listing 93.853 across FY2024–FY2026, from public federal spending records.
- FY2024 obligated
- $1.8B
- FY2025 obligated
- $1.8B
- FY2026 (to date) obligated
- $1.4B
- Awards in window
- 9,485
Top recipients: The General Hospital Corporation, Regents of the University of California, San Francisco, the, The Johns Hopkins University, Regents of the University of Michigan, The Trustees of Columbia University in the City of New York
Source: USAspending.gov · refreshed August 2026
Synopsis
Who can apply
- Independent school districts
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Special district governments
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Private institutions of higher education
- For profit organizations other than small businesses
- Native American tribal governments (Federally recognized)
- County governments
- Public and State controlled institutions of higher education
- Small businesses
- State governments
- City or township governments
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Eligible applicants must be clinical trial sites that participate in a phase 2/3 or phase 3 efficacy clinical trial (designed to provide pivotal data to support a marketing application) supported by a small business concern that is the FDA-designated sponsor of a drug or biological product which is the subject of an IND under section 505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)) to prevent, diagnose, mitigate, treat, or cure ALS. The definition of a small business concern can be found in section 3(a) of the Small Business Act (15 U.S.C. 632(a)).Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
How to apply
Applications go through the official government listing. Grants Radar links you straight to the source — applying is free.
New to federal funding? How to read an announcement · Who can apply · How grants work
Get grants like this every Tuesday — free
One email a week: the biggest new federal grants and what’s closing soon — the same list for everyone. Unsubscribe in one click.
Similar grants
- Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)
- Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
- Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award (CTSA) Program (R03 Clinical Trial Optional)
- Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)
- Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)
- Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)
Same-day alerts, matched to you
The free digest is weekly — the same list for everyone. Members get an alert the day a matching federal grant posts: we read every new Grants.gov posting and score it, personalized to your organization. Free for 30 days, then $19/mo founding rate locked for life — the rate holds while your subscription stays active (Terms). Card required, cancel any time before day 31.
See pricing